Please login to the form below

Not currently logged in
Email:
Password:

Tradjenta

This page shows the latest Tradjenta news and features for those working in and with pharma, biotech and healthcare.

FDA clears Jardiance combo for type 2 diabetes

FDA clears Jardiance combo for type 2 diabetes

In March they secured FDA approval for Glyxambi, which places empagliflozin alongside the active ingredient in their DPP-4 inhibitor product Tradjenta (linagliptin), ahead of competition from AZ and

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics